These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33061257)

  • 41. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.
    Visco DM; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2022 Aug; 28(8):892-902. PubMed ID: 35687793
    [No Abstract]   [Full Text] [Related]  

  • 42. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.
    Leonardi A; Doan S; Aragona P; Amrane M; Ismail D; Montero J; Németh J; Bremond-Gignac D
    Eye (Lond); 2023 Aug; 37(11):2320-2326. PubMed ID: 36564576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature.
    Rhee MK; Mah FS
    Clin Ophthalmol; 2017; 11():1157-1166. PubMed ID: 28790800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.
    Ofri R; Lambrou GN; Allgoewer I; Graenitz U; Pena TM; Spiess BM; Latour E
    Vet J; 2009 Jan; 179(1):70-7. PubMed ID: 17950639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy.
    Gao J; Schwalb TA; Addeo JV; Ghosn CR; Stern ME
    Cornea; 1998 Nov; 17(6):654-63. PubMed ID: 9820947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
    Schneider E; Paulsen F; Jacobi C
    Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca.
    Lee HB; Choi HJ; Cho SM; Kang S; Ahn HK; Song YJ; Kim YJ; Son WC
    Curr Eye Res; 2018 Jul; 43(7):889-895. PubMed ID: 29634381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.
    Coassin M; Lambiase A; Costa N; De Gregorio A; Sgrulletta R; Sacchetti M; Aloe L; Bonini S
    Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):151-5. PubMed ID: 15650854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease.
    Gire AI; Karakus S; Ingrodi SM; Akpek EK
    J Ocul Pharmacol Ther; 2016 Apr; 32(3):150-4. PubMed ID: 26789928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A mouse model of keratoconjunctivitis sicca.
    Dursun D; Wang M; Monroy D; Li DQ; Lokeshwar BL; Stern ME; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):632-8. PubMed ID: 11867577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
    Shen Lee B; Toyos M; Karpecki P; Schiffbauer J; Sheppard J
    Ophthalmol Ther; 2022 Aug; 11(4):1333-1369. PubMed ID: 35608780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca.
    Song XJ; Li DQ; Farley W; Luo LH; Heuckeroth RO; Milbrandt J; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2003 Oct; 44(10):4223-9. PubMed ID: 14507865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tear protein profiles vs. clinical characteristics of untreated and cyclosporine-treated canine KCS.
    Fullard RJ; Kaswan RM; Bounous DI; Hirsh SG
    J Am Optom Assoc; 1995 Jul; 66(7):397-404. PubMed ID: 7560726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the effect of cyclosporine-A 0.05% emulsion on the ocular surface and corneal sensation following cataract surgery.
    Hamada S; Moore TC; Moore JE; Al-Dreihi MG; Anbari A; Shah S
    Cont Lens Anterior Eye; 2016 Feb; 39(1):15-9. PubMed ID: 26275686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.